{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T13:12:00Z","timestamp":1771333920732,"version":"3.50.1"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Oral mifepristone combined with rivanol lactate (rivanol) is commonly used in second-trimester pregnancy termination. However, rivanol is not suitable to premature rupture of membranes and oligohydramnios because amniocentesis is difficult. Mifepristone combined with misoprostol is suitable for the patients with oligohydramnios. In accordance with the misoprostol dosing recommendations by the International Federation of Gynecology and Obstetrics (FIGO), the incidences of uterine rupture and cervical laceration are relatively high in Chinese pregnant women. The aim of our study was to optimize misoprostol dosing regimen in terms of efficacy and safety in Chinese pregnant women.<\/jats:p>\n            <jats:p>We modified the Bishop Score, and then gave patients low-dose misoprostol according to the modified Bishop score. Based on the amniotic fluid volume (AFV) indicated by type-B ultrasonic instrument, the cases with AFV \u22642\u200acm receiving low-dose misoprostol combined with mifepristone and the cases with amniocentesis failure followed by receiving low-dose misoprostol combined with mifepristone were enrolled into study group, and the cases with AFV &gt;2\u200acm receiving rivanol combined with mifepristone were enrolled into control group. The start time of uterine contractions, time of fetal expulsion, birth process, hospital day, successful induced labor rate, complete induced labor rate, and incomplete induced labor rate were observed and compared between the 2 groups.<\/jats:p>\n            <jats:p>There were significant differences in the start time of uterine contractions, time of fetal expulsion, birth process, and hospital day between the control group and the study group (all <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05). The successful induced labor rate, complete induced labor rate, and incomplete induced labor rate were also significantly different between the 2 groups (all <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05).<\/jats:p>\n            <jats:p>In the induced labor of 16 to 28 weeks pathological pregnancy, low-dose misoprostol can markedly improve the successful induced labor rate and complete induced labor rate, shorten the birth process and hospital day, and decrease uterine curettage rate and uterine rupture risk. Low-dose misoprostol combined with mifepristone is suitable to the induced labor of 16 to 28 weeks pathological pregnancy in Chinese women.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000017396","type":"journal-article","created":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T15:13:51Z","timestamp":1570029231000},"page":"e17396","source":"Crossref","is-referenced-by-count":8,"title":["Clinical application of low-dose misoprostol in the induced labor of 16 to 28 weeks pathological pregnancies (a STROBE-compliant article)"],"prefix":"10.1097","volume":"98","author":[{"given":"Yan","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-ming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2019,10]]},"reference":[{"key":"R1-20230915","first-page":"184","article-title":"Comparison of Ethacridine, Mifepristone, Misoprostol for induced labor in second trimester pregnancy with scarred uterus","volume":"9","author":"Hong-ying","year":"2012","journal-title":"China Med Herald"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"584652","DOI":"10.1155\/2011\/584652","article-title":"Silent uterine rupture with the use of misoprostol for second trimester termination of pregnancy: a case report","volume":"2011","author":"Cuellar Torriente","year":"2011","journal-title":"Obstet Gynecol Int"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/931497","article-title":"Complete cervical avulsion with intravaginal misoprostol for second trimester pregnancy termination","volume":"2012","author":"Sajjan","year":"2012","journal-title":"Case Rep Obstet Gynecol"},{"key":"R4-20230915","first-page":"80","article-title":"Observation on the efficacy of vaginal low-dose misoprostol in second trimester pregnancy termination","volume":"14","author":"Si","year":"2015","journal-title":"J China Presc Drug"},{"key":"R5-20230915","first-page":"508","article-title":"Selection of common methods for second trimester pregnancy termination","volume":"25","author":"Huang","year":"2017","journal-title":"Chin J Fam Plan"},{"key":"R6-20230915","first-page":"83","article-title":"Uterine rupture and cervical laceration caused by Rivanol during second trimester pregnancy termination: a report of 12 cases","volume":"6","author":"Li","year":"2005","journal-title":"Pract Clin Med"},{"key":"R7-20230915","first-page":"16","article-title":"Therapeutic efficacy of misoprostol versus ethacridine lactate in second trimester abortion randomised controlled study","volume":"3","author":"Deliwala","year":"2013","journal-title":"Natl J Med Res"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4103\/0366-6999.151073","article-title":"Clinical analyses of 66 cases of mid-trimester pregnancy termination in women with prior cesarean","volume":"128","author":"Peng","year":"2015","journal-title":"Chin Med J (Engl)"},{"key":"R9-20230915","first-page":"829","article-title":"Clinical analysis of 18 cases with complete uterine rupture","volume":"15","author":"Wang","year":"2012","journal-title":"Chin J Coal Ind Med"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ijgo.12181","article-title":"FIGO's updated recommendations for misoprostol used alone in gynecologyand obstetrics","volume":"138","author":"Morris","year":"2017","journal-title":"Int J Gynaecol Obstet"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/jog.12147","article-title":"Randomized controlled trial comparing efficacy between a vaginal misoprostol loading and non-loading dose regimen for second-trimester pregnancy termination","volume":"40","author":"Pongsatha","year":"2014","journal-title":"J Obstet Gynaecol Res"},{"key":"R12-20230915","first-page":"170","article-title":"Uterine rupture caused by mifepristone combined with misoprostol during second trimester pregnancy termination: a case report","volume":"8","author":"Gao","year":"2015","journal-title":"Chin J Clin Rational Drug Use"},{"key":"R13-20230915","first-page":"399","article-title":"Uterine rupture associated with the use of intravaginal misoprostol during second-trimester pregnancy termination","volume":"61","author":"Syed","year":"2011","journal-title":"J Pak Med Assoc"},{"key":"R14-20230915","first-page":"736","article-title":"Study on the changes of blood concentration of Misoprostol in different routes","volume":"12","author":"Shu-ping","year":"2010","journal-title":"Chin J Fam Plan"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/0091270007309707","article-title":"Pharmacokinetic profiles of controlled-release hydrogel polymer vaginal inserts containing misoprostol","volume":"48","author":"Powers","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jgyn.2013.11.008","article-title":"Use of misoprostol for induction of labor in case of fetal death or termination of pregnancy during second or third trimester of pregnancy: efficiency, dosage, route of administration, side effects, use in case of uterine scar","volume":"43","author":"Clouqueur","year":"2014","journal-title":"Gynecol Obstet Biol Reprod (Paris)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017396","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T21:41:26Z","timestamp":1694814086000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":16,"journal-issue":{"issue":"40","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000017396","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}